Norwegian diabetes expert Lifecare AS has gone public on the Oslo stock exchange. The sensor maker plans to fund the next phase of development for its implantable glucose sensor.
Bioscience investment firm Abingworth has closed its latest fund at US$315m (€268m). The money will go to life sciences companies in Europe and the US.
After €7m went to Nextbiotix last week, another financing round is bringing money to a young French biotech. Strasbourg-based Dynacure attracted €47m from investors to bring its lead candidate for centronuclear myopathy into clinical development.
Microbiome start-up Nextbiotix raised € 7m in a Series A round. The Paris-based biotech uses commensal bacteria as drugs to treat major inflammatory bowel diseases.
Dialysis product and service provider Fresenius Medical Care has placed €500m notes. Yesterday, the medtech giant had to come to terms with a sharp drop in share price.
The 33rd edition of Chemspec Europe, International Exhibition for Fine and Speciality Chemicals, ended after two successful show days with record visitor numbers. From 20 to 21 June 2018, a total of 4,202 trade visitors came to the exhibition grounds of the Koelnmesse in Cologne, Germany, where international experts of the fine and speciality chemicals industry met for Europes leading exhibition. These figures represent an increase of visitor numbers by nearly 9% compared to last years show in Munich.
Researchers at VTT Technical Research Centre of Finland have developed a vaccine, diluted into drinking water, to treat diarrhoea on piglets being weaned. The vaccine is expected to reduce the global resistance problem caused by excessive antibiotic use.
VarmX will use the combination of a €7.5m Series A financing co-led by BioGeneration Ventures (BGV) and Dutch regional development company InnovationQuarter plus an €5m innovation credit from the Netherlands Enterprise Agency (RVO.nl) to develop a modified blood coagulation factor X to prevent severe bleeding in haemophilia patients.
The EMAs CHMP recommended nine medicines including six orphan medicines for EU market approval on Friday.
German and US researchers have designed a mouse model that exactly mimics the mechanisms of hepatitis infection in men.